Patent · US Active

Compositions and methods for inhibiting expression of a gene from the JC virus

US8410261B2 · kind B2 · utility

0Cited by

4References

6Claims

0Family size

Assignee

Alnylam Pharmaceuticals, Inc. · US

Inventors

Pamela Tan · Kulmbach, DE
Dinah Wen-Yee Sah · Boston, US
Birgit Bramlage · Ebikon, CH

Key dates

Filing date	Oct 4, 2011
Grant date	Apr 2, 2013
Priority date	—
Expiry date	Oct 4, 2031

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC12N2310/321
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

The invention relates to a double-stranded ribonucleic acid (dsRNA) for inhibiting the expression of a gene from the JC Virus (JC virus genome), comprising an antisense strand having a nucleotide sequence which is less that 30 nucleotides in length, generally 19-25 nucleotides in length, and which is substantially complementary to at least a part of a gene from the JC Virus. The invention also relates to a pharmaceutical composition comprising the dsRNA together with a pharmaceutically acceptable carrier; methods for treating diseases caused by JC virus expression and the expression of a gene from the JC Virus using the pharmaceutical composition; and methods for inhibiting the expression of a gene from the JC Virus in a cell.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.